Dihydrotestosterone(DHT)

立即咨询

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

521-18-6

包装与价格：

包装	价格(元)
25mg	电议
100mg	电议

产品介绍

化学性质

Physical Appearance	A solid
Storage	Store at -20°C
M.Wt	290.44
Cas No.	521-18-6
Formula	C₁₉H₃₀O₂
Solubility	≥29 mg/mL in DMSO; insoluble in H2O; ≥13.6 mg/mL in EtOH
Chemical Name	(5S,8R,9S,10S,13S,14S,17S)-17-hydroxy-10,13-dimethyltetradecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one
Canonical SMILES	C[C@]12CCC(C[C@]1([H])CC[C@@]3([H])[C@]4([H])CC[C@H](O)[C@@](CC[C@@]32[H])4C)=O
运输条件	蓝冰运输或根据您的需求运输。
一般建议	为了使其更好的溶解，请用37℃加热试管并在超声波水浴中震动片刻。不同厂家不同批次产品溶解度各有差异，仅做参考。若实验所需浓度过大至产品溶解极限，请添加助溶剂助溶或自行调整浓度。溶液形式一般不宜长期储存，请尽快用完。

资料参考

Dihydrotestosterone is an endogenous androgen sex steroid and hormone and a potent agonist of the androgen receptor .

In AR-positive bladder cancer UMUC3 and TCC-SUP cells, dihydrotestosterone (DHT) increases the expression of EGFR and ERBB2 both in mRNA and in protein levels. In AR-positive cell，DHT additionally upregulates the levels of phosphorylation of EGFR (pEGFR) and its downstream proteins AKT (pAKT) and ERK1/2 (pERK), induced by EGF treatment[1].

DHT-treated SOD1-G93A mice demonstrate ameliorated muscle atrophy and increased body weight, which is associated with stronger grip-strength. DHT treatment increases the expression of insulin-like growth factor-1 in muscle, which can exert myotrophic as well as neurotrophic effects through retrograde transport. DHT treatment attenuates neuromuscular junction denervation, and axonal and motoneuron loss. DHT-treated SOD1-G93A mice demonstrates improvement in motor behavior as assessed by rota-rod and gait analyses, and an increased lifespan[2].

References:

[1]. Zheng Y, Izumi K, Yao J L, et al. Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells. Endocrine Related Cancer, 2011, 18(4): 451-464.

[2]. Young-Eun Y, Chien-Ping K, Lin M. Dihydrotestosterone Ameliorates Degeneration in Muscle, Axons and Motoneurons and Improves Motor Function in Amyotrophic Lateral Sclerosis Model Mice. PLoS ONE, 2012, 7(5): e37258-.

试验操作

Cell experiment:[1]
Cell lines	Androgen receptor-positive bladder cancer UMUC3 and TCC-SUP cells
Reaction Conditions	1 or 10 nM dihydrotestosterone for 24 h incubation
Applications	Dihydrotestosterone treatment at 1 nM for 24 h increased EGFR levels to 1.7- and 1.9-fold in UMUC3 and TCC-SUP cell lines respectively, compared with mock treatment. Similarly, dihydrotestosterone treatment resulted in up to 1.7-fold increase in ERBB2 levels in both cell lines. Dihydrotestosterone was found to increase EGFR and ERBB2 transcript abundance in both cell lines in a dose-dependent manner.
Animal experiment:[2]
Animal models	SOD1-G93A mice
Dosage form	An estimated plasma concentration of ~ 500 ng/dl Administered in the form of silastic implant
Applications	Dihydrotestosterone treatment ameliorated degeneration in muscle, axons and motoneurons, as well as improved motor function in amyotrophic lateral sclerosis (ALS) model mice. Application of dihydrotestosterone was a relatively simple and non-invasive procedure, which could be translated into therapy to improve the quality of life for ALS patients.
Note	The technical data provided above is for reference only.
	References: 1. Zheng Y, Izumi K, Yao JL, et al. Dihydrotestosterone upregulates the expression of epidermal growth factor receptor and ERBB2 in androgen receptor-positive bladder cancer cells. Endocrine-Related Cancer, 2011, 18(4): 451-464. 2. Yoo YE, Ko CP. Dihydrotestosterone ameliorates degeneration in muscle, axons and motoneurons and improves motor function in amyotrophic lateral sclerosis model mice. PLoS One, 2012, 7(5): e37258.